POTE ankyrin domain family member K, pseudogeneGenealiases: ACT · ACTBL3 · POTE2delta · POTEK
Q-omics provides the consensus-scored POTEKP profile across patient tissues and cancer cell-line models. POTEKP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, POTEKP is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, POTEKP RNA expression shows 12,016 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, and THYM as cancer lineages where POTEKP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEKP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEKP survival associations across molecular data types. POTEKP RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEKP RNA expression–survival associations across cancer types. High POTEKP expression shows unfavorable associations in ACC, LUAD, STAD, LGG and LUSC, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for POTEKP RNA expression.
This table summarizes POTEKP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for POTEKP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEKP shows lower tumor expression in THCA and higher tumor expression in BRCA, HNSC, COAD, LUSC and LIHC. The BRCA box plot shows higher POTEKP RNA expression in tumor versus normal tissue (log2 FC = +0.836, t-test p < 0.001).
This table shows molecular features associated with POTEKP in patient tissues and cancer cell lines. In patient samples, POTEKP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEKP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and NCI60_ALL.
